Glucose
- Generic Name
- Glucose
- Brand Names
- Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- IY9XDZ35W2
- Background
Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines.
- Indication
Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.
- Associated Conditions
- Arrhythmia, Caloric Deficit, Edema of the cerebrum, Hypoglycemia, Metabolic Alkalosis
- Associated Therapies
- Blood Specimen Collection, Electrolyte replacement, Nutritional supplementation, Parenteral Nutrition, Parenteral rehydration therapy, Plasmapheresis, Positive cardiac inotropic effect, Total parenteral nutrition therapy, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy
Sweetheart Study: Oral Glucose for Reducing Stress During Echocardiographic Assessment in Infants in the NICU
- Conditions
- Cardiac Echocardiography Assessment
- Interventions
- Drug: Glucose 25% oral solutionOther: Oral water
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Children's & Women's Health Centre of British Columbia
- Target Recruit Count
- 104
- Registration Number
- NCT01253889
- Locations
- 🇨🇦
Children's & Women's Health Centre of BC, Vancouver, British Columbia, Canada
Clarithromycin as Immunomodulator for the Management of Sepsis
- Conditions
- Septic ShockSevere SepsisSepsis
- Interventions
- Drug: Dextrose 5%
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 600
- Registration Number
- NCT01223690
- Locations
- 🇬🇷
2nd Department of Surgery, University of Thessaloniki, Thessaloniki, Greece
🇬🇷2nd Department of Medicine, Sismanogleion General Hospital, Athens, Greece
🇬🇷4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose
- Conditions
- Knee Osteoarthritis
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Universidad Nacional de Rosario
- Target Recruit Count
- 6
- Registration Number
- NCT01210183
- Locations
- 🇦🇷
Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina
Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis
- Conditions
- End Stage Renal Disease
- Interventions
- Drug: glucose solutions
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 100
- Registration Number
- NCT01170858
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
The Suppression of Toll Like Receptors by Insulin
- Conditions
- Insulin Resistance
- Interventions
- Drug: insulin infusionDrug: Dextrose infusionDrug: Saline Infusion
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT01151605
- Locations
- 🇺🇸
Millard Fillmore Gates Hospital, Buffalo, New York, United States
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 279
- Registration Number
- NCT01075984
Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins
- Conditions
- Hyperglycemia
- Interventions
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 59
- Registration Number
- NCT00995670
- Locations
- 🇺🇸
Zablocki VA Medical Center, Milwaukee, Milwaukee, Wisconsin, United States
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Radiation: 3-D UltrasoundDrug: Adrenocorticotropin
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 41
- Registration Number
- NCT00989781
- Locations
- 🇺🇸
UCSD Medical Center, San Diego, California, United States
Can Enhanced Glycemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Glucose potassium insulin solution
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT00899483
- Locations
- 🇬🇧
University Hospital Birmingham, Birmingham, West Midlands, United Kingdom
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT00878878
- Locations
- 🇺🇸
ICON Development Solutions, Elliott City, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.